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Abstract 
Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) is an emergency skin disease 
with high mortality rates despite the incidence rate is not great. Patients with SJS/TEN will experience 
reduced quality of life due to the pain experienced when eating, drinking or urinating. There is not a 
specific treatment for patient with SJS/TEN so far. Corticosteroids and intravenous immunoglobulin 
(IVIG) are the most commonly used therapies yet there are still controversies due to their positive and 
negative effects. Ulinastatin, a trypsin inhibitor and an anti-inflammatory compound that is made from 
human urine is a therapeutic option for SJS/TEN. Ulinastatin may provide anti-inflammatory effect by 
inhibiting TNF-α production, thereby reducing the risk of septic complications and lowering mortality. 
Until now, the known side effects are nausea, vomiting and allergic to gelatin. Although it has a 
promising potential, the effectiveness of ulinastatin is still poorly studied. Further research is needed 
regarding the usage of ulinastatin on patients with SJS/TEN. 
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Introduction 
 
Stevens-Johnson Syndrome/Toxic Epidermal 
Necrolysis (SJS/TEN) is one of the most 
uncommon diseases. It is an acute skin reaction 
in which skin undergoes inflammatory reaction. 
The reaction stated as SJS if the skin lession 
below 10% of total body area. The lession can 
progress becoming TEN with lession over 30% 
of total body area.Its incidence in the Eastern 
part of the world was approximately 8 case per 
one million population in one year. In 
Indonesia, based on the data from Cipto 
Mangunkusumo Hospital Jakarta, SJS/TEN 
incidence among hospitalized patient from 2009 
to 2011 were 29 people (unpublished data). 
Although it has a small incidence, Stevens-
Johnson Syndrome and Toxic Epidermal 
Necrolysis can attack all races in all ages, with 
men and women ratio 3:5 and had high 
mortality rate. There were 5 to 12 percent SJS 
patients and 30 percent TEN patients died . 
SJS/TEN’s patients may have a lowered quality 
of life. This is due to the involvement of 
mucosa on mouth which causes pain and 
difficulty in eating or drinking. Patients who 
have rashes on the genital area may have 
dysuria or inability to secrete urine. To cope 
with those problems, patients are given many 
kind of treatments such as. However, there is no 
definitive treatment for SJS/TEN. The usage of 
corticosteroid and intravenous immunoglobulin 
(IVIG), which are widely used for this disease, 
are still controversial. 
Corticosteroid has been used as the first line of 
drug for SJS/TEN, but there is controversy 
about its usage. Based on research done by 
Kakourou et al, corticosteroid will shorten fever 
duration compare to SJS/TEN without 
corticosteroid administration. On the other 
hand, Ramussen’s research shows that the usage 
of corticosteroid will prolong the healing time. 
This drug has also been related to increased 
mortality rate, sepsis and prolonged treatment. 
Although it is known for its antibody activity 
which may inhibit or prevent apoptosis, IVIG 
administration as an alternative for SJS/TEN 
has an inconsistent result.A few research show 
a contrast result for its role, for example a study 
done by Trent et al showed that IVIG may 
decrease mortality rate in TEN patient, however 
Bachot et al showed that patients’ mortality 
rate, especially the elderly, increased by 
administrating IVIG. 
Many studies have been conducted to find the 
cure for SJS/TEN, but most of the researches 
are focused on corticosteroid and IVIG instead 
of alternative treatments which may effectively 
treat SJS/TEN, such as ulinastatin. Ulinastatin 
is a compound derived from human urine. 
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Ulinastatin works by inhibiting inflammatory 
response which may cause apoptosis in 
SJS/TEN., 
Research on ulinastatin has been conducted in 
developed countries as a treatment option for 
many inflammatory diseases such as 
pancreatitis and hemorrhagic shock.9, However, 
we found only few  studies regarding to 
ulinastatin’s role in SJS/TEN.  
Stevens-Johnson Syndrome and Toxic 
Epidermal Necrolysis (SJS/TEN) 
Definition and Classification 
Stevens-Johnson Syndrome and Toxic 
Epidermal Necrolysis is an acute idiopathic skin 
reaction on mucocutaneous which is usually 
triggered by consumption of certain drugs. The 
characteristic of this disease is erythema on the 
skin and mucosa layer which followed by 
necrosis and shedding of the skin. If this disease 
is not treated as soon as possible, patient’s life 
may be threatened as it involved various human 
body system.3, 
Usually, Stevens-Johnson Syndrome is often 
known as a variant of major erythema 
multiforme. Toxic Epidermal Necrolysis is a 
variant of Stevens-Johnson Syndrome. These 
two conditions can  occur simultaneously 
although more than 50% of TEN lesion 
developed directly from erythema to necrosis 
followed by epidermal shedding.  Due to this 
reason,  the classification of SJS/TEN is based 
on the total area of the skin loss:3 
1. Less than 10%  : SJS 
2. 10%-30%  : SJS/TEN 
overlapping 
3. More than 30% : TEN 
Risk Factors 
People more than 40 years old has a higher risk 
to develop SJS/TEN. Women are more prone to 
this disease than men with the ratio 0,6.3 Other 
risk factors are Human Immunodeficiency 
Virus (HIV), collagen abnormality and cancer. 
Human Leukocyte Antigen (HLA) also show a 
correlation with the development of SJS/TEN.3, 
Etiology 
The most prevalent etiology is hypereactive 
response to drugs such as carbamazepine. 
However, there are other causes such as 
infections and malignancies. SJS/TEN can also 
be idiopathic 
Pathophysiology 
The pathophysiology of SJS/TEN has not been 
fully understood. Several studies have discussed 
about the mechanism underlying this disease 
such as Gell and Coombs Classification. Gell-
Coombs Classification stated that there are four 
types of  body responses to infectious agents: 
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1. Type I: Anaphylactic reaction (mediated 
by IgE); eg. urticaria. 
2. Type II: IgG/IgM or cytolysis mediated 
reaction (complement activation); eg. 
thrombocytopenia. 
3. Type III: Immune complex-antibody 
response. 
4. Type IV: cellular immunity mediated 
reaction; eg. SJS/TEN. 
  
SJS and TEN are included into type IV 
hypersensitivity, especially type IVc. There are 
four type of type IV hypersensitivity based on 
cytokine and cell type, those are type Iva (via 
monocyte), IVb (via eosinophils), IVc (via CD4 
and CD8 T cell activity), and IVd (neutrophils 
mediated). 
Other factors which may lead to SJS/TEN are 
HLA genes, cytotoxic signals, and immune 
system molecules.3 Human Leukocyte Antigen 
gene play a role in antigen-processing 
presentation and cytotoxic protein may lead to 
SJS/TEN by apoptosis, chemoattractant and 
pro-inflammatory substa nces activation 
via Fas-FasLigand (Fas-FasL) interaction, 
perforin/granzyme B and granulysin.13,, Tumor 
Necrosis Factor (TNF)-α, interleukin (IL)-10, 
interferon (IFN)-γ and other cytokine and 
chemokine may increase in SJS/TEN. TNF-α is 
also found in epidermis keratinocyte and play a 
role in Fas-FasL regulation together with IFN-γ 
and IL-15. 
Reactive Oxygen Species (ROS) also play a 
role in giving contribution to SJS/TEN via 
oxidative stress. Free radical can trigger 
oxidative stress and cause intracellular and cell 
membrane damage. The damage lead to release 
of pro-apoptotic molecules (FasL and TNF-α) 
which cause apoptosis and necrosis.5, 
Inflammation process in Stevens-Johnson 
Syndrome/Toxic Epidermal Necrolysis 
After a susceptible person exposed with the 
causal agents of SJS/TEN (mainly drugs), 
hypersensitivity reaction will emerge from 
his/her body. When the antigen enters the 
immune system, our immune system may 
respond.  The immune response does not 
depend on the size of the molecule. All 
molecules can lead to immune responses. 
Antigens will bind to other macromolecules on 
the surface of the cell or in plasma to form 
hapten-carrier complex. The complex then 
become a multivalent complex and secreted out 
of the cell in the form of Antgen-Presenting 
Cell (APC). These complexes are going to 
trigger the activation of T lymphocyte, B cell or 
Mast Cell. 
There is another theory besides the hapten-
carrier complex theory. This theory is called the 
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p-i concept or “direct pharmacological 
interaction of drugs with immune receptors”. In 
this theory, if drugs occupy the specific position 
of T cell receptor, it may stimulate cytokine 
production, proliferation and cytotoxic effect 
from the T cell. As the result, immune response 
is activated. The p-i concept can cause cross 
sensitivity towards several drugs such as 
carbamazepine.21, 
Those two immune response may be two 
different concepts. However drugs such as 
carbamazepine may trigger both responses. 
SJS/TEN symptoms may be affected by several 
risk factors: genes, keratinocytes, and cytokines 
such as perforin/granzyme B, Fas-FasL receptor 
interaction, granulysin and TNF-α. 21 
Gene Involvement in SJS/TEN 
Wei et al., in his research stated that gene plays 
a role in SJS/TEN pathophysiology. The 
research showed that in vitro, carbamazepine 
and its derivatives can interact with HLA-
B*1502 without cellular metabolism or antigen-
processing presentation. The binding between 
HLA/peptide with the drugs may cause the drug 
to be taken to Cytotoxic T cell and trigger 
immune reaction.15,23 
Keratinocytes 
Keratinocytes have an important role in 
SJS/TEN pathogenesis. Lesion on the skin 
shows that the metabolites which cause 
SJS/TEN are from the skin.13, Enzymatic 
reaction also occurs in keratinocyte, such as 
cytochrome P450 react with carbamazepine on 
SJS/TEN patient’s epidermis.24, T cell migrates 
to keratinocyte and induce a reaction which is 
triggered by  perforin/granzyme B and Fas-
FasLigand receptors (CD95 receptor). After 
that, hypersensitivity type IVc occurs and 
causes SJS/TEN to destroy keratinocytes.20,24   
In SJS/TEN patients, certain drugs can cause 
cellular immunity to react and phagocytes the 
drugs. After phagocytosis, the drug will be 
presented by HLA-B which a class I Major 
histocompatibility complex (MHC) to CD8+ 
cytotoxic T cells.13,25, Nassif et al showed many 
cytotoxic T cells inside the patient’s blisters. T 
lymphocyte would then triggers apoptosis from 
perforin/granzyme B pathway. 
Perforin/Granzyme B 
Perforin and granzyme pathway are initiated by 
perforin which open the way for granzyme to 
cause cell death. Perforin binds to target cell 
membrane. Granzyme B  enters via 
endocytosis. After entering the cell, granzyme 
will bind to mannose-6-phosphate 
receptor/insulin-like growth factor II. When 
perforin gives a signal to release granzyme, 
granzyme would trigger caspase-3 via 
mitochondria and cause DNA fragmentation 
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and apoptosis.  granzyme B also triggers 
apoptosis from the division of BH3-Interacting 
domain death agonist (Bid). Bid will cause 
cytochrome c enter the cytosol and apoptosis 
occur.25 
Fas Receptor and Fas Ligand Interaction 
Keratinocyte may induce FasL expression via 
pro-inflammatory cytokines and the ligand is 
going to bind to Fas receptor.  Fas receptor then 
recruits Fas-associated death domain protein 
(FADD) and pro-caspase 8. Pro-caspase would 
activate caspase 8 to trigger caspase pathway 
and DNA degradation. This would lead to 
keratinocyte apoptosis. , 
Granulysin 
Granulysin may induce apoptosis in SJS/TEN 
patient from different pathways. Granulysin is a 
pro-apoptotic protein which causes cytotoxicity 
at cell and expressed in high amount.7 It is 
found more than perforin/granzyme B and 
soluble FasL in SJS/TEN patients’ blister (2-4 
times more). Granulysin can trigger apoptosis 
pathway by destroying mitochondria. The 
destroyed mitochondria then release 
cytochrome-c and DNA fragmentation leading 
to apoptosis. In addition, binding of granulysin 
to cell membrane can trigger influx of calcium 
into intracellular and apoptosis.,  
Tumor Necrosis Factor (TNF)-α 
TNF-α is involved in apoptosis and necrosis 
pathway by activating caspase, Fas-FasL 
expression, and nitric oxide (Reactive Oxygen 
Species) production. Fas-FasL complex induces 
extrinsic pathway of apoptosis and Reactive 
Oxygen Species (ROS) induces intrinsic 
pathway. In short time, both eventually lead to 
activation of caspase. Activated caspase 
degrades DNA and nucleoproteins, nuclear 
matrix component, and cytoskeleton, leading to 
fragmentation of cells and death. On the other 
hand, these molecules can lead to decline in cell 
membrane integrity and pore permeability in 
long time. Leak of mitochondrial matrix lead to 
cell rupture and necrosis.31,  
Ulinastatin 
General Description 
Ulinastatin is also called urinary trypsin 
inhibitor (UTI), HI-30, or bikunin. It is acid 
glycoprotein with a molecular weight of 67,000 
kDa. Ulinastatin is a serine protease inhibitor 
multivalent Kunitz type, found in human urine 
and blood. The compound consists of 143 
amino acid residues and has two homologous 
domains Kunitz type. 
Ulinastatin is produced by hepatocytes in the 
form of precursors associated with α1-
microglobin. In hepatocytes, ulinastatin pairs 
with one or two of the three evolutionarily 
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related heavy chain (HC) 1, HC 2, HC 3 
through chondroitin sulfate chains forming 
protein structure. 
Pharmacodynamics 
At the time of the inflammatory reaction, 
ulinastatin separates from IαI family protein 
through proteolytic cleavage by neutrophil 
elastase. Several serine proteases such as 
trypsin, thrombin, chymotrypsin, kallikrein, 
plasmin, elastase, cathepsin, and factors IXa, 
Xa, Xia, and XIIa can be inhibited by 
ulinastatin. Ulinastatin has also been reported to 
suppress the expression of urokinase-type 
plasminogen activator (uPA) through inhibition 
of protein kinase C (PKC). 
In humans, ulinastatin has a protective effect 
against ischemic reperfusion injury in the liver, 
kidney, heart, lung, and stomach. Giving 
prepump administration (5000 U/kg) ulinastatin 
repair cardiopulmonary bypass-induced 
hemodynamic instability and lung disorders 
through attenuation of production-release of IL-
6 and IL-8. 
Ulinastatin has only few side effects. The side 
effects include nausea, vomiting, and diarrhea. 
At the injection site, ulinastatin may cause 
angialgia, redness, and itching. Allergic 
reactions can also occur.  
Pharmacokinetics 
Study on pharmacokinetics of ulinastatin still 
very limited. Techpool Bio-Pharma reported 
that provision of 300,000 IU/10 ml ulinastatin 
intravenously (IV) to male subjects, the 
concentration in the blood decreases linearly 
within 3 hours. Its half-life is 40 minutes. After 
6 hours of the initial administration, it has been 
excreted in the urine as much as 24%. 
Clinical Usage 
In the market, the price of ulinastatin can be 
quite high, reaching U.S. $ 130 for 10 mg. The 
unit dose is 1,000,000 IU for every 5 mg 
solution of ulinastatin, depending on the 
concentration of the stabilizer component that 
may be added. Ulinastatin can be administered 
into the human body intravenously with a 
maximum dose of 300,000 U/day. On 
maintenance therapy, the dose used is 2,500-
5,000 U/kg. 
To anticipate the expensive price on the market, 
ulinastatin can be made in the laboratory by 
centrifugation and stabilization from human 
urine using methods by Proksch and Routh.33 
Urine was centrifuged (1000g for 15 min) and 
the supernatant purified to obtain pure 
ulinastatin concentration. Gelatin is used to 
stabilize the compound. 
Giving ulinastatin in patients SJS/TEN reported 
to give good results.48 Erythema, fatigue, and 
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fever showed obvious improvement within 24 
hour of starting ulinastatin therapy. The skin 
lession resolved between 4 to 7 days compared 
10 to 12 days without ulinastatin. Commonly 
used dosage is about 7500 U/kg/day IV for 4-7 
days after the appearance of skin lesions. After 
the lesions disappear, it reduced to 2500-5000 
U/kg/day as maintenance therapy until full 
recovery. Ulinastatin exhibit anti-inflammatory 
activity and reduce the rate of infiltration of 
neutrophils and the release of elastase and 
chemical mediators.34 
Use of ulinastatin reported to have side effects 
such as nausea and vomiting, but it is not life 
threatening. However, gelatin allergies can 
sometimes appear after repeated administration 
of ulinastatin.46 
 
Ulinastatin as Anti-Inflammatory for 
SJS/TEN 
In vitro tests, ulinastatin is reported to inhibit 
the production of TNF-α and IL-1 in 
Lipopolysaccharides (LPS)-stimulated human 
monocytes and HL60 cells or bronchial 
epithelial cells which were stimulated by LPS 
or neutrophil elastase.17, Aosasa et al stated that 
ulinastatin block TNF-α production by 
inhibiting the translation of secretedTNF-α, 
rather than transcription of its mRNA as in 
other trypsin inhibitor compounds. This is 
believed to be the differentiator between 
ulinastatin with trypsin inhibitor compounds 
generally.45 
The concept of ulinastatin work in driving the 
inflammation 
A group of researchers demonstrated the 
performance of in vitro ulinastatin inhibits 
TNF-α-stimulated LPS. LPS binds to soluble 
LPS-binding protein, and both bind to the 
cluster of differentiation (CD) 14 to be 
presented to the LPS receptor Toll-like receptor 
4 (TLR4). TLR4 activates several signaling 
pathways, involving extracellular-signal-
regulated kinase (ERK) 1/2. LPS also activates 
c-Jun N-terminal kinase (JNK) and p38 
mitogen-activated protein kinase (MAPK), 
which increases the translation and stability of 
TNF-α. ERK 1/2 itself acts as a pathway that 
controls the induction of post-transcription 
TNF-α. Suppressing this pathway is likely to be 
the cause of disturbance in translation or 
secretion thus inhibited the production of TNF-
α. However, it remains unknown which specific 
pathways involved until now.7 Furthermore, 
ulinastatin decreases the metabolism rate 
involving the regulation of arachidonic acid, 
such as thromboxane B2 production, which 
plays a role in the pathogenesis of sepsis. Inamo 
et al report concludes therapeutic mechanism of 
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ulinastatin in SJS/TEN includes the stabilization 
of lysosomal membranes, inhibition of 
apoptosis, and suppression of TNF-α activity. 
Comparison with Other SJS/TEN Therapy 
Corticosteroid Therapy 
Corticosteroids are often used as a primary 
treatment in case of SJS/TEN.28 These 
compounds inhibit the function of APC and 
macrophages, as well as affect the inflammatory 
response by reducing the synthesis of 
inflammatory mediators such as prostaglandins, 
leukotrienes, and platelet-activating factors. The 
end result, impaired immune function caused by 
cytotoxic T lymphocytes and macrophages are 
suppressed and inflammation can be inhibited. 
Corticosteroid therapy remains controversial, 
there is the possibility increasing risk of 
complications of sepsis and gastrointestinal 
bleeding.29, Side effects allegedly caused by 
corticosteroids can induce bacterial or viral 
infections or hypercoagulable state in acute 
phase.7 Administration of corticosteroid in 48 
hours or more since onset of disease and 
administration of glucocorticoids in patients 
with TEN does not provide a therapeutic effect. 
A retrospective study concluded that SJS 
treatment with steroids can significantly 
prolong the healing process.28 Halebian et al 
mentioned that the mortality rate among the 
advanced TEN patients with steroid therapy (46 
± 6 years, n = 15) against non-steroid (37 ± 7 
years, n = 15) is 2:1, indicating the danger of 
corticosteroids for patients with TEN. 
Intravenous Immunoglobulin Therapy (IVIG) 
IVIG therapy was first introduced by Viard et al 
in 1998. This treatment resists the CD95 (Fas) 
receptor which induces keratinocyte apoptosis. 
IVIG is produced from blood plasma, 
fractionated and purified to obtain a product 
containing 90-98% IgG, IgA bit, IgM, CD4, 
CD8, HLA, and cytokines.16 
Appropriate dose for this therapy is still 
unclear. Viard et al provide protocol infusion 
dose 0.7 g/kg/day for 4 consecutive days.16 This 
dose is highly modified, ranging from 1.6 
g/kg/day to 3 g/kg/day for 3 days. Variability 
due to lack of consistent and controlled, 
randomized comparative studies. 
Various studies have reported positive results in 
this therapy. However, there are also 
experiments stating poor results of IVIG 
therapy. Brown et al and Bachot et al did not 
demonstrate significant improvement in patient 
mortality with TEN. Elderly patients and those 
with impaired kidney function are also reported 
to have no therapeutic effects.55Prins et al 
suspected cause of patient's diversity response 
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is a variety of anti-Fas activity is higher than 
any IVIG is used. 
 
Ulinastatin Compares with Corticosteroid and 
IVIG 
SJS/TEN usually treated using corticosteroid 
and IVIG. However, both of them still 
controversial, providing unstable results. 
Cortiosteroid also reported to induce 
gastrointestinal bleeding in some cases. Report 
from Inamo et al using ulinastatin giving better 
result compares to corticosteroid and IVIG. 
Fever completely resolved after 24 to 36 hours 
and the mean hospital stay was 11.0 days for 
patients treated by ulinastatin. IVIG gives an 
average 2.5 days to resolve the fever and 11.0 
days for corticosteroid treatment. The mean 
hospital stay for both later treatment was 12.2 
days.52 
 
 
Conclusion 
 
Currently, there is good evidence to suggest that 
there may be a bidirectional relationship 
between T2DM and ALD. Evidence in the 
literature has shown that ALD may influence 
the development of T2DM and vice versa. 
However, there is much less information 
regarding the effects of these two conditions on 
liver function when they occur together. This is 
a notable gap that is of significant importance, 
given the potential for worse liver outcomes 
occurring in these patients in the face of 
epidemics of both conditions in Australia. As 
such, further research in the area needs to occur 
in order to develop well-defined strategies to 
prevent and manage the combined effects of 
T2DM and ALD should they occur 
concurrently. 
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